Efficacy and safety of Yinhua Miyanling tablets in the treatment of acute pyelonephritis
Objective To investigate the efficacy and safety of Yinhua Miyanling tablets in the treatment of acute pyelonephritis(APN).Methods A total of 82 APN patients admitted in our hospital from June 2021 to May 2023 were selected as the research objects,and the patients were divided into control group and study group by random number table method,with 41 cases in each group.The control group was treated with cefotaxime sodium,and the study group was treated with Yinhua Miyanling tablets on the basis of the control group.The clinical efficacy,TCM syndrome scores,renal function indexes,inflammatory indexes and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).After treatment,the TCM syndrome scores of the study group were lower than those of the control group(P<0.05).After treatment,the levels of creatinine(Cr),blood urea nitrogen(BUN),cystatin C(CysC)and microalbumin(MAU)in the study group were lower than those in the control group(P<0.05).After treatment,the levels of hypersensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6)and interleukin-17(IL-17)in the study group were lower than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Yinhua Miyanling tablets can improve the clinical efficacy of APN patients,relieve clinical symptoms,improve inflammatory indexes and renal function indexes,and has high safety.
万方数据
维普
